Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01643603

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Researchers think that dasatinib may cause large granular lymphocyte expansion to happen in patients who have received a blood stem cell transplant (SCT) between 3 to 15 months after the SCT. In this research study, researchers want to find how well dasatinib can be tolerated, the best dose to take of dasatinib and how to estimate how often large granular lymphocytic cellular expansion happens at the best dose of dasatinib.

Status: 
Recruiting
Study Date: 
Tue, 05/01/2012 to Sat, 10/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Dasatinib Patients receive dasatinib PO every day (QD) for 6 months. Other Names: BMS-354825 Sprycel Other: laboratory biomarker analysis Correlative studies